PD-1 (PDCD1) Promoter Methylation Is a Prognostic Factor in Patients With Diffuse Lower-Grade Gliomas Harboring Isocitrate Dehydrogenase (IDH) Mutations

Immune checkpoints are important targets for immunotherapies. However, knowledge on the epigenetic modification of immune checkpoint genes is sparse. In the present study, we investigated promoter methylation of CTLA4, PD-L1, PD-L2, and PD-1 in diffuse lower-grade gliomas (LGG) harboring isocitrate...

Descripción completa

Detalles Bibliográficos
Autores principales: Röver, Lea Kristin, Gevensleben, Heidrun, Dietrich, Jörn, Bootz, Friedrich, Landsberg, Jennifer, Goltz, Diane, Dietrich, Dimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835568/
https://www.ncbi.nlm.nih.gov/pubmed/29396294
http://dx.doi.org/10.1016/j.ebiom.2018.01.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835568/
https://www.ncbi.nlm.nih.gov/pubmed/29396294
http://dx.doi.org/10.1016/j.ebiom.2018.01.016

Ejemplares similares